View Older Stories View More Recent Stories

Jun 24, 2020 08:00AM Daré Bioscience Announces Publication of a Peer-Reviewed Journal Article Supporting the Use of the Postcoital Test Study as a Predictor of Contraceptive Effectiveness by Biology of Reproduction
Jun 17, 2020 08:02AM Dare Bioscience (DARE) Begins Pivotal Phase 3 Study of DARE-BV1 in Patients with Bacterial Vaginosis
Jun 17, 2020 08:00AM Daré Bioscience Announces Initiation of Pivotal Phase 3 Study of DARE-BV1 in Patients with Bacterial Vaginosis
Jun 15, 2020 08:04AM Dare Bioscience (DARE) Announces Receipt of $1.5 Million Under Current Grant Supplement Award for Continued Development of User-Controlled Long Acting Reversible Contraceptive
Jun 15, 2020 08:00AM Daré Bioscience Announces Receipt of $1.5 Million Under the Current Grant Supplement Award for Continued Development of User-Controlled Long Acting Reversible Contraceptive
Jun 4, 2020 08:00AM Daré Bioscience Announces Participation in BIO Digital 2020
May 14, 2020 08:00AM Daré Bioscience Reports First Quarter 2020 Financial Results and Provides Company Update
May 11, 2020 08:10AM Dare Bioscience (DARE), Health Decisions Form Strategic Partnership to Accelerate the Development of Daré’s Novel Pipeline of Women’s Health Programs
May 11, 2020 08:00AM Daré Bioscience and Health Decisions Form Strategic Partnership to Accelerate the Development of Daré’s Novel Pipeline of Women’s Health Programs
May 7, 2020 08:00AM Daré Bioscience to Host First Quarter 2020 Financial Results and Company Update Conference Call and Webcast on May 14, 2020
Apr 28, 2020 08:00AM Daré Bioscience CEO to Participate in Maxim Group’s Infectious Disease Virtual Conference
Apr 23, 2020 08:05AM Dare Bioscience (DARE) Enters Common Stock Purchase Agreement for up to $15 Million with Lincoln Park Capital Fund, LLC
Apr 23, 2020 08:00AM Daré Bioscience Announces Common Stock Purchase Agreement for up to $15 Million with Lincoln Park Capital Fund, LLC
Apr 1, 2020 08:00AM Daré Bioscience Receives Third Notice of Award from National Institutes of Health Eunice Kennedy Shriver National Institute of Child Health and Human Development for the Development of Ovaprene®
Mar 30, 2020 08:00AM Daré Bioscience Reports 2019 Financial Results and Provides a Company Update
Mar 24, 2020 08:00AM Daré Bioscience to Host Fourth Quarter and Full-year 2019 Financial Results and Company Update Conference Call and Webcast on March 30, 2020
Mar 10, 2020 08:14AM Dare Bioscience (DARE) Receives FDA Fast Track Designation for DARE-BV1 for the Treatment of Bacterial Vaginosis
Mar 10, 2020 08:00AM Daré Bioscience Receives FDA Fast Track Designation for DARE-BV1 for the Treatment of Bacterial Vaginosis
Mar 9, 2020 08:08AM Dare Bioscience (DARE) Presents Positive Sildenafil Cream, 3.6% Data Supporting Further Development for the Treatment of Female Sexual Arousal Disorder
Mar 9, 2020 08:00AM Daré Bioscience Presents Positive Sildenafil Cream, 3.6% Data Supporting Further Development for the Treatment of Female Sexual Arousal Disorder
Feb 27, 2020 08:00AM Daré Bioscience to Present at the Cowen 40th Annual Health Care Conference
Feb 6, 2020 08:19AM Dare Bioscience (DARE) Regains Compliance with Nasdaq Minimum Equity Rule and Secures Capital to Advance Product Candidates
Feb 6, 2020 08:00AM Daré Bioscience Regains Compliance with Nasdaq Minimum Equity Rule and Secures Capital to Advance Product Candidates
Feb 6, 2020 08:00AM Daré Bioscience Regains Compliance with Nasdaq Minimum Equity Rule and Secures Capital to Advance Product Candidates
Feb 6, 2020 08:00AM Daré Bioscience Regains Compliance with Nasdaq Minimum Equity Rule and Secures Capital to Advance Product Candidates
Feb 5, 2020 08:00AM Daré Bioscience to Present at the 2020 BIO CEO & Investor Conference
Feb 5, 2020 08:00AM Daré Bioscience to Present at the 2020 BIO CEO & Investor Conference
Feb 5, 2020 08:00AM Daré Bioscience to Present at the 2020 BIO CEO & Investor Conference
Jan 30, 2020 08:05AM Dare Bioscience (DARE) Regains Compliance with Nasdaq Minimum Bid Price Rule
Jan 30, 2020 08:00AM Daré Bioscience Regains Compliance with Nasdaq Minimum Bid Price Rule
Jan 30, 2020 08:00AM Daré Bioscience Regains Compliance with Nasdaq Minimum Bid Price Rule
Jan 15, 2020 08:00AM Daré Bioscience Schedules Conference Call for January 22, 2020 to Discuss Ovaprene® Licensing Agreement and General Corporate Update
Jan 15, 2020 08:00AM Daré Bioscience Schedules Conference Call for January 22, 2020 to Discuss Ovaprene® Licensing Agreement and General Corporate Update
Dec 18, 2019 08:07AM Dare Bioscience (DARE) Reports FDA Clearance of IND Application for DARE-BV1 for Bacterial Vaginosis to Commence Pivotal Phase 3 Clinical Study
Dec 18, 2019 08:00AM Daré Bioscience Announces FDA Clearance of IND Application for DARE-BV1 for Bacterial Vaginosis to Commence Pivotal Phase 3 Clinical Study
Dec 18, 2019 08:00AM Daré Bioscience Announces FDA Clearance of IND Application for DARE-BV1 for Bacterial Vaginosis to Commence Pivotal Phase 3 Clinical Study
Dec 11, 2019 08:07AM Dare Bio (DARE) Announces Alignment with FDA on Phase 2b Study Design, Primary Endpoint PRO Instruments to Support Development of Sildenafil Cream, 3.6%, for Female Sexual Arousal Disorder
Dec 11, 2019 08:00AM Daré Bioscience Announces Alignment with the FDA on Phase 2b Study Design and Novel Primary Endpoint PRO Instruments to Support the Continued Clinical Development of Sildenafil Cream, 3.6%, a Potenti
Dec 11, 2019 08:00AM Daré Bioscience Announces Alignment with the FDA on Phase 2b Study Design and Novel Primary Endpoint PRO Instruments to Support the Continued Clinical Development of Sildenafil Cream, 3.6%, a Potenti
Dec 10, 2019 08:00AM Daré Bioscience Announces Feature Presentation at the15th US-Japan Symposium on Drug Delivery Systems
Dec 10, 2019 08:00AM Daré Bioscience Announces Feature Presentation at the15th US-Japan Symposium on Drug Delivery Systems
Nov 21, 2019 08:00AM Daré Bioscience Closes Previously Announced Acquisition of Microchips Biotech with a First-in-Class Wireless, User-Controlled Drug Delivery Platform
Nov 14, 2019 08:00AM Daré Bioscience Reports Third Quarter 2019 Financial Results and Provides Company Update
Nov 14, 2019 08:00AM Daré Bioscience Reports Third Quarter 2019 Financial Results and Provides Company Update
Nov 12, 2019 08:00AM Daré Bioscience Announces Positive Findings from a Postcoital Test Clinical Study of Ovaprene® Hormone-Free Contraceptive Candidate
Nov 12, 2019 08:00AM Daré Bioscience Announces Positive Findings from a Postcoital Test Clinical Study of Ovaprene® Hormone-Free Contraceptive Candidate
Nov 11, 2019 08:07AM Dare Bioscience (DARE) Reports Acquisition of Microchips Biotech Inc.
Nov 11, 2019 08:00AM Daré Bioscience Enters into Agreement to Acquire Microchips Biotech Including Its First-in-Class Wireless, User-Controlled Drug Delivery Platform
Nov 7, 2019 08:30AM Daré Bioscience to Host Third Quarter 2019 Financial Results and Company Update Conference Call and Webcast
Nov 7, 2019 08:30AM Daré Bioscience to Host Third Quarter 2019 Financial Results and Company Update Conference Call and Webcast
View More Recent Stories View Older Stories